132 related articles for article (PubMed ID: 37902259)
1. Essential cancer medicines and cancer outcomes: Cross-sectional study of 124 countries.
Ikpeni OT; Maraj D; Woods H; Workentin A; Booth CM; Persaud N
Cancer Med; 2023 Nov; 12(22):20745-20758. PubMed ID: 37902259
[TBL] [Abstract][Full Text] [Related]
2. Essential diabetes medicines and health outcomes in 127 countries.
Budhram D; Benipal S; Bilimoria K; Maraj D; Wang R; Persaud N
Diabetes Obes Metab; 2021 May; 23(5):1121-1128. PubMed ID: 33417268
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study.
Adekoya I; Maraj D; Steiner L; Yaphe H; Moja L; Magrini N; Cooke G; Loeb M; Persaud N
Lancet Infect Dis; 2021 Oct; 21(10):1429-1440. PubMed ID: 34332706
[TBL] [Abstract][Full Text] [Related]
4. Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list.
Maraj D; Steiner L; Persaud N
J Clin Tuberc Other Mycobact Dis; 2022 May; 27():100305. PubMed ID: 35308809
[TBL] [Abstract][Full Text] [Related]
5. Access to Cytotoxic Medicines by Children With Cancer: A Focus on Low and Middle Income Countries.
Barr R; Robertson J
Pediatr Blood Cancer; 2016 Feb; 63(2):287-91. PubMed ID: 26375626
[TBL] [Abstract][Full Text] [Related]
6. Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries.
Bazargani YT; Ugurlu M; de Boer A; Leufkens HGM; Mantel-Teeuwisse AK
BMC Cardiovasc Disord; 2018 Jun; 18(1):126. PubMed ID: 29940880
[TBL] [Abstract][Full Text] [Related]
7. Essential medicines for breast cancer in low and middle income countries.
Bazargani YT; de Boer A; Schellens JH; Leufkens HG; Mantel-Teeuwisse AK
BMC Cancer; 2015 Aug; 15():591. PubMed ID: 26283654
[TBL] [Abstract][Full Text] [Related]
8. A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list.
Naicker I; Suleman F; Perumal-Pillay VA
J Pharm Policy Pract; 2022 Dec; 15(1):97. PubMed ID: 36482421
[TBL] [Abstract][Full Text] [Related]
9. Selection of Blood, Blood Components, and Blood Products as Essential Medicines in 105 Low- and Middle-Income Countries.
Samukange WT; Gardarsdottir H; Leufkens HGM; Mantel-Teeuwisse AK
Transfus Med Rev; 2020 Apr; 34(2):94-100. PubMed ID: 31761652
[TBL] [Abstract][Full Text] [Related]
10. Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists.
Bazargani YT; de Boer A; Leufkens HG; Mantel-Teeuwisse AK
PLoS One; 2014; 9(9):e106072. PubMed ID: 25259517
[TBL] [Abstract][Full Text] [Related]
11. Essential medicines availability is still suboptimal in many countries: a scoping review.
Mahmić-Kaknjo M; Jeličić-Kadić A; Utrobičić A; Chan K; Bero L; Marušić A
J Clin Epidemiol; 2018 Jun; 98():41-52. PubMed ID: 29452222
[TBL] [Abstract][Full Text] [Related]
12. Associations between essential medicines and health outcomes for cardiovascular disease.
Steiner L; Fraser S; Maraj D; Persaud N
BMC Cardiovasc Disord; 2021 Mar; 21(1):151. PubMed ID: 33765933
[TBL] [Abstract][Full Text] [Related]
13. A comparison of national essential medicines lists in the Americas.
Steiner L; Maraj D; Woods H; Jarvis J; Yaphe H; Adekoya I; Bali A; Persaud N
Rev Panam Salud Publica; 2020; 44():e5. PubMed ID: 31998375
[TBL] [Abstract][Full Text] [Related]
14. Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists.
Jarvis JD; Woods H; Bali A; Oronsaye E; Persaud N
PLoS One; 2019; 14(8):e0220781. PubMed ID: 31398195
[TBL] [Abstract][Full Text] [Related]
15. Selection of oncology medicines in low- and middle-income countries.
Bazargani YT; de Boer A; Schellens JH; Leufkens HG; Mantel-Teeuwisse AK
Ann Oncol; 2014 Jan; 25(1):270-6. PubMed ID: 24356638
[TBL] [Abstract][Full Text] [Related]
16. Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa.
Petricca K; Kambugu J; Githang'a J; Macharia WM; Njuguna F; McLigeyo A; Nyangasi M; Orem J; Kanyamuhunga A; Laiti R; Katabalo D; Schroeder K; Rogo K; Maguire B; Wambui L; Nkurunziza JN; Wong B; Neposlan J; Kilawe L; Gupta S; Denburg AE
Lancet Oncol; 2023 May; 24(5):563-576. PubMed ID: 37023781
[TBL] [Abstract][Full Text] [Related]
17. Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda.
Kizub DA; Naik S; Abogan AA; Pain D; Sammut S; Shulman LN; Martei YM
Oncologist; 2022 Nov; 27(11):958-970. PubMed ID: 36094141
[TBL] [Abstract][Full Text] [Related]
18. Determinants of access to childhood cancer medicines: a comparative, mixed-methods analysis of four Caribbean countries.
Boateng R; Petricca K; Tang B; Parikh S; SinQuee-Brown C; Alexis C; Browne-Farmer C; Reece-Mills M; Salmon SM; Bodkyn C; Gupta S; Maguire B; Denburg AE
Lancet Glob Health; 2021 Sep; 9(9):e1314-e1324. PubMed ID: 34416215
[TBL] [Abstract][Full Text] [Related]
19. The role of government agencies and other actors in influencing access to medicines in three East African countries.
Odoch WD; Dambisya Y; Peacocke E; Sandberg KI; Hembre BSH
Health Policy Plan; 2021 Apr; 36(3):312-321. PubMed ID: 33569583
[TBL] [Abstract][Full Text] [Related]
20. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.
Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM
Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
